|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||399.86 g/mol|
Arbaclofen placarbil (ar-BAC-loe-fen pla-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|